<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Overexpression of transforming growth factor alpha (TGF-alpha) and epidermal growth factor receptor (EGFR) occurs in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, particularly the specialized type, which is at an increased risk for <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We performed this study to evaluate the immunohistochemical expression and prognostic significance of these growth factors, as well as MiB-1, the Ki-67 proliferation-associated nuclear antigen, in Barrett's-associated <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Monoclonal antibodies for TGF-alpha, EGFR, and MiB-1 were evaluated in 25 cases of Barrett's-associated <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (BAA) and in adjacent areas of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>The data were correlated with the pathologic features (grade, stage, depth of invasion, lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>) and the clinical outcome of the patients </plain></SENT>
<SENT sid="4" pm="."><plain>Of the BAAs, 100% and 64% were positive for TGF-alpha and EGFR, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>TGF-alpha and EGFR expression did not correlate with any of the pathologic features of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>By univariate analysis, a higher degree of EGFR immunostaining was significantly associated with poorer patient survival (P = 0.004) </plain></SENT>
<SENT sid="7" pm="."><plain>After stratified analysis, however, EGFR expression correlated with poor survival only in patients with pathologic Stage II <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (P = 0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>There was significant (P &lt; 0.001) increase in the MiB-1 proliferation index (PI) associated with <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e>: Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, 22.0% +/- 6.4; <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 56.5% +/- 21.6; and BAA, 70.0% +/- 17.7 </plain></SENT>
<SENT sid="9" pm="."><plain>In a separate comparison of the <z:chebi fb="2" ids="8069">luminal</z:chebi> (upper half) and basal (lower half) crypt MiB-1 PI, dysplastic epithelium revealed a significant increase in the <z:chebi fb="2" ids="8069">luminal</z:chebi> crypt MiB-1 PI in comparison with Barrett's metaplastic epithelium (50.7 +/- 24.6 versus 1.2 +/- 1.9, P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>EGFR expression might have prognostic value for patients with BAA, particularly those with Stage II <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The MiB-1 PI pattern supports the <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> pathogenetic sequence in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Furthermore, the pattern of MiB-1 immunostaining might help to distinguish dysplastic from regenerative metaplastic epithelium of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> in uncertain cases </plain></SENT>
</text></document>